To Patients
Sarcoidosis ILD
Intervention Type:
Subcutaneous (SC) Injection
Funder Type:

Drug Details

Acthar® Gel (repository corticotropin injection) is FDA approved for the treatment of people with symptoms of sarcoidosis.

Study Purpose

The purpose of this study is to find out if Acthar Gel is safe and effective to treat pulmonary sarcoidosis. Participants will be randomly assigned (like flipping a coin) to receive a shot under their skin of Acthar Gel or a matching placebo gel that has no drug in it. They will receive their assigned shot twice a week for 24 weeks. All participants who complete the 24-week treatment period will be eligible to receive Acthar Gel for 24 more weeks, even if they were originally in the placebo group.

This drug has no clinical trials actively recruiting patients at this time.